P&G on UVA
Procter & Gamble submits additional UVA efficacy data supporting the addition of avobenzone combined with either 2-pherrylbenzimidazole-5 sulfonic acid (PBSA) or zinc oxide in the final sunscreen monograph. The in vivo data show 1.5% PBSA with 3% avobenzone had a protection factor of 3.6, versus 1.4 for PBSA alone. Similarly, 4% zinc oxide combined with 3% avobenzone had a 5.6 protection factor compared to 2.3 with zinc oxide alone. P&G originally submitted safety data on the ingredients after a Jan. 27 "feedback" meeting with the agency ("The Tan Sheet" March 15, In Brief). FDA found the data insufficient ("The Tan Sheet" April 26, p. 9)
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.